Status:

COMPLETED

Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU)

Lead Sponsor:

University Hospital, Tours

Collaborating Sponsors:

Centre Hospitalier Universitaire, Amiens

University Hospital, Angers

Conditions:

Hemolytic-Uremic Syndrome, Atypical

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Eculizumab is an anti-C5 monoclonal antibody approved for rare diseases including atypical haemolytic-uraemic syndrome. The maintenance phase dosing regimen is identical for all adult patients but sev...

Detailed Description

Eculizumab is a very expensive drug (450 000 euros per year per patient). According to the usual administration scheme, the eculizumab is administrated by intravenous infusion, every 14 or 21 days in ...

Eligibility Criteria

Inclusion

  • Adults with an atypical Hemolytic and Uremic Syndrome defined by at least 2 of the following parameters:
  • Thrombopenia (platelet count \< 150 G/L)
  • Mechanical lytic anemia (Hb \< 10 g/L, Lactate dehydrogenase \> upper limit of normal, undetectable haptoglobin, presence of schistocytes on blood smear)
  • Acute renal failure
  • Eculizumab treatment
  • Without project of withdrawal in the next 18 months
  • Started since at least 6 months
  • Administrated with an unchanged administration schedule since at least 3 months (initial episode or relapse)
  • Atypical Hemolytic and Uremic Syndrome in remission
  • Patients who give informed consent.

Exclusion

  • Patients on dialysis.
  • Women treated starting or planning a pregnancy.
  • Patients suffering from a typical or secondary microangiopathic hemolytic anemia (drugs, malignancies, autoimmune disease...)
  • Patients under protection of a judicial authority

Key Trial Info

Start Date :

October 20 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 28 2023

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04859608

Start Date

October 20 2021

End Date

December 28 2023

Last Update

March 25 2025

Active Locations (18)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (18 locations)

1

CHU Amiens Picardie

Amiens, France

2

CHU d'Angers

Angers, France

3

Hôpital Tenon

APHP Tenon, France

4

CHU Besançon

Besançon, France

Personalized Spacing of Eculizumab Infusions Based on Therapeutic Pharmacological Monitoring (EspacECU) | DecenTrialz